Molecular docking, a tool to determine interaction of CuO and TiO2 nanoparticles with human serum albumin

Sandesh Chibber, Irshad Ahmad

1. Introduction

Human serum albumin (HSA) is one of the important transport proteins in the human blood and can bind to any ligand that injected into blood stream thus play important role in drug delivery system. Structurally, a single polypeptide chain of HSA consists of 585 amino acids. HSA consists of three homologous domains (I, II, and III) and each comprised of subdomain A and B. The subdomains IIA and IIIA of HSA consists of high affinity ligand binding sites and is referred as Sudlow’s site I and II, respectively [1,2].

The high surface areas and unusual crystal morphologies endue CuO NPs with antimicrobial activity. CuO NPs are most frequently used as antimicrobial (antiviral, antibacterial, antifungal), antibiotic treatment alternatives, nanocomposite coating, catalyst, lubricants. Also, used in applications like gas sensors, fungi), antibiotic treatment alternatives, nanocomposite coating, used as antimicrobial (antiviral, antibacterial, antifouling, antimicrobial). CuO NPs with antimicrobial activity. CuO NPs are most frequently used in biomedical applications that include the photodynamic therapy for cancer treatment, drug delivery systems, cell imaging, biosensors for biological assay, and genetic engineering. High physical and chemical stability of CuO and TiO2 nanoparticles renders their extreme use in catalytic applications [3]. TiO2 NPs drive a strong interest, subsequently intensive experimental and theoretical studies, owing to its unique photocatalytic properties, excellent biocompatibility, and high chemical stability. TiO2 NPs are used widely in biomedical applications that include the photodynamic therapy for cancer treatment, drug delivery systems, cell imaging, biosensors for biological assay, and genetic engineering. High physical and chemical stability of CuO and TiO2 nanoparticles renders their extreme use in catalytic applications [4]. However, Nanotoxicology is come forth in the field of toxicology to address the gaps in knowledge and adverse health effects associated with CuO and TiO2 nanomaterials. CuO NPs exposure results in significantly elevated level of antioxidant enzymes. CuO NPs has also been found to induce hepatotoxicity and nephrotoxicity. CuO NPs can equally exhibit neurotoxicity and similar toxicity but to lesser extent as compared to CuO NPs [9–12]. Thus, it is very important to understood interaction mechanism of CuO NPs and TiO2 NPs with serum albumin and accordingly reduces CuO NPs and TiO2 NPs vulnerability in the system thereby minimizing its toxic effects.

Keywords: CuO NP, TiO2 NP, HSA, Subdomain III A, Sudlow site I, Sudlow site II
The binding affinity of a ligand with serum albumin helps us to understand its bioavailability, distribution, and elimination from the body. HSA can bind a notable variety of drugs affecting their delivery and efficacy and ultimately altering the drug's pharmacokinetic and pharmacodynamic properties. Additionally, HSA is widely used in clinical assumptions as a drug delivery system due to its potential for improving targeting while decreasing the side effects of drugs. Nanoparticles such as CuO and TiO₂ are widely used in medical application such as drug delivery system [13,14]. Subsequently, the affinity between HSA and nanoparticles as legend becomes crucial interest to study in order to determine nanoparticles binding potential with circulating protein. The binding study conducted through molecular docking can help to infer the duration of its half-life that consequently reveals the efficacy of nanomedication [1]. Drug delivery mechanism is propagated through serum albumin. In order to introduce CuO NPs and TiO₂ NPs in nanodelivery it is most worthy for the researchers to be aware about interaction sites and the region involve in binding with serum albumin so that nanoparticles itself may not become inhibitor for the drug binding sites. Therefore, present study conducted on the comparison of binding affinity of serum albumin with CuO and TiO₂ nps. Thus, it may provide valuable information concerning their therapeutic efficacies.

2. Methods

Molecular docking studies were carried out using AutoDock 4.2 tool to predict the preferred binding mode and binding sites of TiO₂ and CuO with HSA. The structure of TiO₂ and CuO was drawn using ACD/ChemSketch and its geometry was optimized by combine use of Gaussian 03 program and Autodock 4.2. The crystal structure of HSA (PDB ID: 1E7I) was obtained from Protein Data Bank [15]. Before docking analysis Hetatm were removed from the protein and the energy was minimized by SPDBV-Swiss-pdbviewer. For docking calculations, Lamarckian genetic algorithms (LGA) were used and grid parameters were set as 126/C0/C126, with a spacing of 1 Å, in AutoDock 4.2. To determine the preferred binding sites on HSA, TiO₂, and CuO molecules were allowed to move within the whole region of HSA via 50 runs to obtain the possible binding gesture. The output from AutoDock was further analyzed with PyMOL and UCSF Chimera software package [16,17].

3. Results

3.1. Different residues in HSA protein and their distances from tryptophan in case of CuO np-HSA interaction

The preferable binding of CuO nanoparticles to HSA protein obtained was through polar residue Arg 472 residue and through Lys 475, Glu 492, Ala 490, Cys 487, Ala 490 bond formation. The measured distances between the surfaces of the CuO np and Arg residue (subdomain IIA) site II obtained were 2.113 Å, 2.410 Å, with Glu having 1.713 Å as shown in Fig. 1. Therefore, these sites would be the probable binding sites of HSA with CuO nanoparticles.

3.2. Geometrical accommodation and the chemical environment of domain in HSA in case of CuO np-HSA binding

4 hydrogen bonds were predicted involving hydrogen atoms from three different amino acid residues of HSA (Arg-472, Gln-492 and Ala 490) as shown in Fig. 2. Lys 475, Glu 492 residue are charged groove of HSA bind with CuO nanoparticle as depicted in Fig. 3.

3.3. Different residues in HSA protein and their distances from surface of TiO₂ np-HSA interaction

The preferable binding of TiO₂ nanoparticles to HSA protein obtained was through polar hydrophilic amino acids Arg 257 residue and thorough Ala 258, Ser 287, His 288, Leu 283, Ala 254, Tyr 150 form bond formation with TiO₂ np. The measured distances between the surfaces of the TiO₂ np and Arg residue (subdomain II A) obtained were 2.536 Å. However, 2.916 Å, 2.631 Å, 1.779 Å, 2.563 Å, 2.920 Å and 1.572 Å is the bond length with respective amino acids of bound region as shown in Fig. 4. Therefore, these sites would be the probable binding sites of HSA with TiO₂ nanoparticle.

3.4. Geometrical accommodation and the chemical environment of domain in HSA in case of TiO₂ np-HSA binding

4 hydrogen bonds were predicted involving hydrogen atoms from three different amino acid residues of HSA (Tyr 150, Ser-287 and Arg 257) as shown in Fig. 5. Leu 283, Leu 284, Glu 285, Lys 286 residue form hydrophobic pocket of HSA that bind with TiO₂ nanoparticle as depicted in Fig. 6.

3.5. Binding energy predicted for CuO np-HSA interaction and TiO₂ np-HSA interaction

The predicted binding models of CuO with the lowest docking energy (−1.644 kcal mol⁻¹) at site II of HSA were used for binding orientation analysis. Whereas, in case of TiO₂ nanoparticle the lowest docking energy obtained was −2.47 kcal mol⁻¹ (Table 1) at the binding region.

4. Discussion

Amino acid sequence of human serum albumin (HSA) consists of 18 tyrosines, 6 methionines, 1 tryptophan (Trp 214), 17 disulfide bridges, and only one free thiol (Cys 34) residue. HSA comprises of three homologous domains (I, II, and III) that assemble to form a cordate molecule. The hydrophobic pockets at subdomains IIA and IIIA is the main regions of ligand interaction with IIIA having the highest affinity for the interaction [2,18]. In our study the whole region of HSA
was selected in order to predict binding of HSA with CuO and TiO₂ nanoparticle for the autodock. Many ligands bind specifically to HSA, either in site I (located at subdomain IIA) or in site II (located at subdomain IIIA). In our case CuO bind to site II, subdomain IIIA and TiO₂ nanoparticle bind to site I located at subdomain IIA. The single tryptophan of HSA at residue 214 has been used extensively for binding studies [19]. From the protein structural data the distances from the centre of subdomain IIIA to Arg-472 (subdomain IIIA) was found to be 2.113 Å whereas on entering the grid for TiO₂ nanoparticle the region predicated by Autodock 4.2 is Arg 257 (subdomain IIA) with bond length of 2.536 Å. The structural information that derives from this study for CuO and TiO₂ may be useful for designing these nanoparticles based drug delivery system considering in terms of both high and low-affinity binding sites. This is helpful in order to avoid binding to HSA, or to make use of its depot function for the delivery purpose.

The attachment of CuO nanoparticles at the site II may be explained by considering the geometrical arrangement (Arg-472, Gln-492 and Ala 490) surrounded by the environment of charged pocket Lys 475, Glu 492 of the domain (subdomain IIIA) in HSA. However in case of TiO₂ nanoparticle structural binding residue involved were Arg 257, Ala 258, Ser 287, His 288, Leu 283, Ala 254, Tyr 150 at the interior hydrophobic binding pocket and comprise loop helix features of HSA at subdomain IIA. The other residues which was docked were Ser-287, Leu 283, Leu 284, Glu 285, Lys 286 this show that TiO₂ np interact with both the cluster of polar residues at suldow site II (subdomain II A) of HSA protein [13]. Upon CuO nanoparticle binding, Lys 475 from subdomain III A moves to interact with the Cu moiety of the nanoparticle bound to a site that straddles domains II. However, TiO₂ nanoparticle docked with Lys 286 at subdomain II A which is referred as suldow site I. Both the nanoparticle protrudes with aliphatic region at front end of the pocket at respective domain. This interaction helps to compare the

---

**Fig. 2.** Graphical representation of HSA-CuO nanoparticle complex. Hydrophobic moieties involve in interactions with CuO NPs are shown as graphical representation.

**Fig. 3.** Aliphatic region identification of HSA-CuO nanoparticle interaction. The surrounding residue of the binding region of HSA that forms groove with CuO NPs.

**Fig. 4.** Residual interactions at the HSA-TiO₂ nanoparticle interface in HSA. Schematic representations of different residues in HSA protein and their distances from centre subdomain II A.
relative binding groove residues at sudlow site I and II respectively for each nanoparticle and has a large impact on only one side of HSA for respective nanoparticle that could correspond to drug binding site. Furthermore, in case of TiO₂-HSA interaction extensive rearrangement of the H-bond network occurs between residues Arg 257, Ala 258, Ser 287, His 288, Leu 283, Ala 254, Tyr 150 with nanoparticle and this may result in increase in pocket volume for drug like azapropazone which are specific for sudlow site I [13]. The success rate of docking for region predicted for the binding in case of both CuO np-HSA and TiO₂ np-HSA interaction was considered by an observed binding energy as it was found to be $\Delta G < 0$.

The general anesthetic propofol has also been shown to bind to Sudlow’s site II (subdomain IIIA) in a cavity that able to host the diiodophenol ring of a thyroxine molecule as well [20]. The general anesthetic halothane also binds to Sudlow’s site II. Since, we have also predicted that CuO nanoparticle also bind to Sudlow’s site II i.e, subdomain III A thus can be used with thyroxine in exploring the pharmacokinetics, and may increase vulnerability of thyroxin in blood stream after binding with serum albumin protein, subsequently, can also serve as inhibitor for thyroxine to bind with albumin protein and to understand its mechanism more clearly. However, TiO₂ np bind to site I there-by can be use as competitive inhibitor for phenylbutazone by competing at sudlow site 1 and can protrude in drug binding efficacy. Moreover, indomethacin (IMN) azapropazone (AZP) drug can bind to subdomain II A. studies have shown that because of nanomaterials property large surface to volume ratio they are used frequently in drug delivery system. Considering TiO₂ NPs binding mode with subdomain II A, TiO₂ Nps can be used as nanocomposite for indomethacin (IMN) as well as with azapropazone (AZP) drug in a drug delivery system [12].

Subdomain III A in HSA has also been reported to possess esterase like activity (hydrolysis of $p$-nitrophenol esters) [21]. As discussed CuO nanoparticle bind to subdomain III A thus binding of these nanoparticles to this region may influence esterase like activity of Serum albumin protein. Thus, CuO np can be variably used with different alkaloids for its effectiveness by targeting esterase like activity of serum albumin protein [21].

The 4-Phenylbutyric acid (4-PBA) is a drug used in disease conditions like type 2 diabetes, obesity and neurodegeneration [22]. It alleviates endoplasmic reticulum stress by assisting protein

| Table 1 |
| --- |
| Binding energy obtained for CuO nanoparticle HSA interaction and TiO₂ nanoparticle HSA Interaction by molecular docking approach. Binding energy generated is higher in case of CuO NPs as compared to TiO₂ NPs HSA interaction. |
| TiO₂ | CuO |
| Binding energy | $-2.47 \text{ kcal mol}^{-1}$ | $-1.64 \text{ kcal mol}^{-1}$ |

Fig. 5. Graphical representation of HSA-TiO₂ nanoparticle complex. Residues involved in the hydrophobic interactions are shown in graphical form.

Fig. 6. Aliphatic region of HSA-TiO₂ nanoparticle complex. The surrounding residue of HSA that forms groove with TiO₂ NPs.

The general anesthetic propofol has also been shown to bind to Sudlow’s site II (subdomain IIIA) in a cavity that able to host the diiodophenol ring of a thyroxine molecule as well [20]. The general anesthetic halothane also binds to Sudlow’s site II. Since, we have also predicted that CuO nanoparticle also bind to Sudlow’s site II i.e, subdomain III A thus can be used with thyroxine in exploring the pharmacokinetics, and may increase vulnerability of thyroxin in blood stream after binding with serum albumin protein, subsequently, can also serve as inhibitor for thyroxine to bind with albumin protein and to understand its mechanism more clearly. However, TiO₂ np bind to site I there-by can be use as competitive inhibitor for phenylbutazone by competing at sudlow site 1 and can protrude in drug binding efficacy. Moreover, indomethacin (IMN) azapropazone (AZP) drug can bind to subdomain II A. studies have shown that because of nanomaterials property large surface to volume ratio they are used frequently in drug delivery system. Considering TiO₂ NPs binding mode with subdomain II A, TiO₂ Nps can be used as nanocomposite for indomethacin (IMN) as well as with azapropazone (AZP) drug in a drug delivery system [12].

Subdomain III A in HSA has also been reported to possess esterase like activity (hydrolysis of $p$-nitrophenol esters) [21]. As discussed CuO nanoparticle bind to subdomain III A thus binding of these nanoparticles to this region may influence esterase like activity of Serum albumin protein. Thus, CuO np can be variably used with different alkaloids for its effectiveness by targeting esterase like activity of serum albumin protein [21].

The 4-Phenylbutyric acid (4-PBA) is a drug used in disease conditions like type 2 diabetes, obesity and neurodegeneration [22]. It alleviates endoplasmic reticulum stress by assisting protein
folding. The molecular docking study on 4-PBA explores the binding nature of 4-PBA with human serum albumin (HSA) and reported that 4-PBA has high binding specificity to Suldow Site II (subdomain IIA). The suldow site II also knows as Fatty acid binding site 3, (subdomain III A). We can say based on our analysis that CuO nanoparticles bind to subdomain III A i.e fatty acid binding site 3 thus CuO can also be study for drug delivery approach for 4-PBA in-order to understand its kinetics. Moreover, CuO could also be applied with application like micelles formation to overruled fatty acid binding potential with serum albumin protein by targeting fatty acid binding site 3 in HSA protein.

5. Conclusions

HSA comprises of three homologous domains (I, II, and III) that assemble to form a cordate molecule. The hydrophobic pockets at subdomains IIA and IIIA is the main regions of ligand interaction with IIIA having the highest affinity for the interaction. In our study the whole region of HSA was selected in order to predict binding of HSA with CuO and TiO2 nanoparticle. We have exploited CuO nanoparticle bind to site II, subdomain III A and TiO2 nanoparticle bind to site I located at subdomain II A of HSA protein. Thus, it can be inferred that both CuO and TiO2 nanoparticles showed HSA binding properties, with TiO2 nanoparticle having a slightly higher affinity towards HSA. This is attributed on the basis of the binding energy which is less in case of TiO2 nanoparticle as compared to CuO nanoparticle.

Acknowledgements

The authors sincerely acknowledge ICMR New Delhi for the award of Research Associateship to S.C. Communication number allotted by ILS is ILS-56.

Appendix A. Transparency document

Transparency document associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.bbrep.2016.03.004.

References

[1] T. Peters, All About Albumin Biochemistry, Genetics, and Medical Applications, Academic Press, San Diego 1996, p. 382.
[2] D.C. Carter, J.X. Ho, Structure of serum albumin, Adv. Protein Chem. 45 (1994) 153–203.
[3] P.K. Stoimenov, R.L. Klinger, G.L. Marchin, K.J. Klambunde, Metal oxide nanoparticles as bactericidal agents, Langmuir 18 (2002) 6679–6686.
[4] G. Ren, D. Hu, E.W.C. Cheng, M.A. Vargas-Res, P. Reip, R.P. Allaker, Characterisation of copper oxide nanoparticles for antimicrobial applications, Int. J. Antimicrob. Agents 33 (2009) 587–590.
[5] F. Buikce, K. Thiel, R. Dringen, Uptake and toxicity of copper oxide nanoparticles in cultured primary brain astrocytes, Nanotoxicology 8 (2014) 775–785.
[6] M. Douadi, M. Setokt, Acute effect of nano-copper on liver tissue and function in rat, J. Nanomed. 1 (2014) 331–338.
[7] A. Pal, M. Siotto, R. Prasad, R. Squitti, Towards a unified vision of copper involvement in Alzheimer’s disease: a review connecting basic, experimental, and clinical research, J. Alzheimers Dis. 44 (2015) 343–354.
[8] A. Pal, Copper toxicity induced hepatoencephalic and neurodegenerative diseases: an urgent need for prognostic biomarkers, Neurotoxicology 40 (2014) 97–101.
[9] T. Benedicte, R. Ramune, W. Aya, S. Parrisa, H.S. Robert, Titanium dioxide nanoparticles induce DNA damage and genetic instability in vivo in mice, Cancer Res. 69 (2009) 8784–8789.
[10] C. Peng, T. Akiyoshi, Detection of DNA damage response caused by different forms of titanium dioxide nanoparticles using sensor cells, J. Biosens. Bioelectron. 3 (2012) 5.
[11] C.I. Vamanu, M.R. Cimpan, P.J. Hol, S. Sornes, S.A. Lie, N.R. Gjerdet, Induction of cell death by TiO2 nanoparticles: studies on a human monoclastoid cell line, Toxicol. In Vitro 22 (2008) 1689–1696.
[12] J.X. Wang, C.Y. Chen, Y. Liu, F. Jiao, W. Li, F. Lao, Y.F. Li, B. Li, C.C. Ge, G.Q. Zhou, Y. X. Gao, Y.L. Zhao, Z.F. Chai, Potential neurological lesion after nasal instillation of TiO2 nanoparticles in the anastute and rutile crystal phases, Toxicol. Lett. 183 (2008) 72–80.
[13] F. Yang, Y. Zhang, H. Liang, Interactive association of drugs binding to human serum albumin, Int. J. Mol. Sci. 15 (2014) 3580–3595.
[14] F.Y. Zi, Wu Long, G.Y. Hua, S. Yong Hua, Recent progress in biomedical applications of titanium dioxide, Phys. Chem. Chem. Phys. 15 (2013) 4844–4858.
[15] D.S. Goodsell, G.M. Morris, A.J. Olson, Automated docking of flexible ligands: applications of AutoDock, J. Mol. Recognit. 9 (1996) 1–5.
[16] M. Amiri, K. Janieje, J.K. Albani, Characterization of human serum albumin forms with pH. Fluorescence lifetime studies, Pharm. Biomed. Anal. 51 (2010) 1097–1102.
[17] K. Flora, J.D. Brennan, C.A. Baker, M.A. Doody, F.V. Bright, Unfolding of acrylodan-labeled human serum albumin probed by steady-state and time-resolved fluorescence methods. Biophys. J. 75 (1998) 1084–1096.
[18] G. Zolese, G. Falcioni, E. Bertoli, R. Galeazzi, M. Wozniak, Z. Wypych, E. Gratton, A. Ambrosini, Steady-state and time resolved fluorescence of albumins interacting with N-oleylethanolamine a component of the endogenous N-acyl-lethanolamines, Proteins Struct. Funct. Bioinf. 40 (2000) 39–48.
[19] M. Amiri, K. Janieje, J.R. Albani, Origin of fluorescence lifetimes in human serum albumin. Studies on native and denatured proteins, J. Fluor. 20 (2010) 651–656.
[20] F. Mauro, C. Stephen, T. Enzo, G. Monica, F. Gabriella, N. Pasquale, N. Stefania, A. Paolo, The extraordinary ligand binding properties of human serum albumin, JUBMB Life 57 (2005) 787–796.
[21] R. Samira, S. Yalda, G. Sirous, B. Nooshin, G. Saeed, M. Nastaran, A. K. Mohammad Reza, A. Abbas, K. Reza, Studies of the interaction between isoimperatorin and human serum albumin by multispectroscopic method, Sci. World J. (2013) 305081.
[22] D. Roy, V. Kumar, J. James, M.S. Shihabudeen, S. Kulshrestha, V. Goel, et al., Evidence that chemical chaperone 4-phenylbutyric acid binds to human serum albumin at fatty acid binding sites, PLoS One 10 (2015) e0133012.